Clinical Trials in Dallas

Showing 2341-2360 of 17,468 trials

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Zydus Therapeutics Inc.240 participantsStarted Sep 2025

La Jolla, California, United States • Orange, California, United States • San Francisco, California, United States +14 more locations

RECRUITING< 1 mile

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875

A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.

AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates2,000 participantsStarted May 2024

Little Rock, Arkansas, United States • Irvine, California, United States • Los Angeles, California, United States +87 more locations

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Find Trials by Condition in Dallas

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

A Study of MGC026 in Participants With Advanced Solid Tumors

A Study of CTD402 in T-ALL/LBL Patients

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

A Study of EBC-129 in Advanced Solid Tumours

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

International CRDS Registry

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice